Instead, clinical and preclinical data demonstrate an association between CD276 expression and poor prognosis, reduced TILs infiltration, impaired anti-tumor responses by CD8+ T cells and NK cells, as well as heightened metastasis across several cancer types, such as pancreatic, esophageal, and cervical cancer [127,128,129,130]. This evidence concerns the gene CD276 and neoplasm.